European Union regulators’ slow progress on authorizing cannabidiol derived from Cannabis sativa L. for use in dietary supplements has prompted a Czech Republic-based manufacturer to seek approval for synthetic CBD as a novel food. The firm believes intransigence on the part of regulatory authorities may be caused by the stigma attached to cannabis-derived CBD, a stigma which it says a synthetic product has the potential to overcome.
The manufacturer, CBDepot, is a subsidiary of Cannabis Pharma, the first company to lodge a novel food application with the European
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?